Dr. Matthew Galsky interprets latest atezolizumab/chemo results in bladder cancer
Galsky highlights final OS data from the IMvigor130 trial, along with an exploratory analysis examining outcomes by type of chemotherapy used.
Galsky highlights final OS data from the IMvigor130 trial, along with an exploratory analysis examining outcomes by type of chemotherapy used.
UroViu’s portable and versatile disposable cystoscopy platform delivers consistent performance, on par with reusable scopes, advancing clinical care, and limiting disposable waste. The benefit of…
“[This] shows a different approach for detecting circulating tumor DNA in bladder cancer patients, and it opens up the possibility for other biorepositories that have…
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year
The test, which was launched in Canada in September 2023, is available through Nanostics’ accredited laboratory in Edmonton, Alberta.
“We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and…
“Results from these trials show that giving physicians an alert informing them of their patient’s actual risk for antibiotic resistance can help them choose the…
“Ultimately, we found that in this retrospective evaluation, there was no significant difference in recurrence-free survival in those who are treated with gemcitabine and docetaxel…
All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Jaideep S. Sohi, MD, shares his vision for the future of PSMA-PET imaging in prostate cancer.